Ken Griffin Cardiol Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 29,400 shares of CRDL stock, worth $72,912. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,400
Previous 33,700
12.76%
Holding current value
$72,912
Previous $60,000
1.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.47MCall Options Held
162KPut Options Held
7.4K-
Tejara Capital LTD London, X01.72MShares$4.27 Million1.26% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.47MShares$3.64 Million0.55% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9924KShares$2.29 Million0.36% of portfolio
-
Lion Street Advisors, LLC253KShares$628,1360.19% of portfolio
-
Cambridge Investment Research Advisors, Inc.116KShares$288,0040.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $154M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...